Table 2.
Incidence of adverse effects in the induction phase in 492 patients studied for whom toxicity data were available at this stage of treatment. Panel A shows the data for the SR group; Panel B for the ImR group. Bolds are used to indicate significant values.
| Panel A | PEG − DNR+ | PEG + DNR+ | PEG + DNR− | p | |||
|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | ||
| Total number of patients | 101 | 100 | 99 | 100 | 83 | 100 | |
| Amylase (>2–5 × UNL) | 0 | 0 | 2 | 2.0 | 2 | 2.4 | 0.317 |
| Fibrinogen (>40% reduction) | 3 | 3.0 | 13 | 13.1 | 11 | 13.3 | 0.020 |
| Thrombosis (deep vein thrombosis, need AC therapy or embolism) | 2 | 2.0 | 1 | 1.0 | 1 | 1.2 | 0.829 |
| Hyperglycemia (>13.9 mmole/L) | 1 | 1.0 | 2 | 2.0 | 1 | 1.2 | 0.812 |
| Infection | 58 | 57.4 | 57 | 57.6 | 52 | 62.6 | 0.725 |
| Panel B | PEG− | PEG+ | p | ||||
| n | % | n | % | ||||
| Total number of patients | 111 | 100 | 98 | 100 | |||
| Amylase (>2–5 × UNL) | 1 | 0.9 | 3 | 3.1 | 0.255 | ||
| Fibrinogen (>40% reduction) | 10 | 9.0 | 12 | 12.2 | 0.447 | ||
| Thrombosis (deep vein thrombosis, need AC therapy or embolism) | 1 | 0.9 | 1 | 1.0 | 0.929 | ||
| Hyperglycemia (>13.9 mmole/L) | 3 | 2.7 | 7 | 7.1 | 0.133 | ||
| Infection | 69 | 62.2 | 66 | 67.3 | 0.434 | ||
UNL—upper normal limit; AC—anticoagulant.